Hanmi Pharm signs anticancer technology export of KRW 1 trillion with Genentech

Published: 2016-10-04 09:00:13

Updated: 2016-10-04 09:00:13

Hanmi Pharm announced conclusion of a license agreement for the development and commercialization of HM95573, a targeted therapy under development for Phase 1 clinical trials, with an affiliate of Roche, Genentech, on the 29^th.

Thus, Genentech now owns the exclusive right to develop and commercialize HM95573 in the world but Korea.

If succeeding in clinical development, approval and commercia...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.